LRRK2 and progressive supranuclear palsy: Recent GWAS investigating the rate of progression of a tauopathy in progressive supranuclear palsy identified variants in a putative enhancer for LRRK2 that increase the rate of progression, implicating LRRK2 in mediating tauopathy pathogenesis (Jabbari et al, 2021).